|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C225H348N48O68• XNa |
|||
| Molecular Weight | 4813.45 | CAS No. | 2023788-19-2 (free base) | |
| Solubility (25°C)* | In vitro | DMSO | 100 mg/mL (20.77 mM) | |
| Water | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Tirzepatide (LY3298176, GIP/GLP-1 RA, TZP) sodium is a dual GIP/GLP-1 receptor agonist. Tirzepatide differentially induces internalization of the GIP and GLP-1 receptors with EC50 values of 18.2 nM and 18.1 nM, respectively. | |||||
|---|---|---|---|---|---|---|
| Targets |
|
|||||
| In vitro | In HEK293 cells, Tirzepatide induces internalization of the GIPR and has a propensity toward partial agonism, and this ultimately reflects in signaling bias toward the cAMP pathway versus β-arrestin recruitment.[1] |
|||||
| In vivo | LY3298176 shows glucose-dependent insulin secretion and improves glucose tolerance by acting on both GIP and GLP-1 receptors in mice. Chronic treatment with LY3298176 results in a significant dose-dependent decrease in body weight that is more pronounced than that observed with semaglutide.[2] |
|||||
| Density | 95.0~105.0% | |||||
Protocol (from reference)
References
|
Selleck's Tirzepatide (LY3298176) sodium has been cited by 5 publications
| Evidence that tirzepatide protects against diabetes-related cardiac damages [ Cardiovasc Diabetol, 2024, 23(1):112] | PubMed: 38555463 |
| Tirzepatide prevents neurodegeneration through multiple molecular pathways [ J Transl Med, 2024, 22(1):114] | PubMed: 38287296 |
| Tirzepatide attenuates mammary tumor progression in diet-induced obese mice [ bioRxiv, 2024, 2024.01.20.576484] | PubMed: 38328151 |
| Tirzepatide attenuates mammary tumor progression in diet-induced obese mice [ bioRxiv, 2024, 23:2024.01.20.576484.] | PubMed: 38328151 |
| Protection of pancreatic islets from oxidative cell death by a peripherally-active morphinan with increased drug safety [ Mol Metab, 2023, 75:101775] | PubMed: 37451343 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.